

CAT's views on classification of ATMPs: homologous use



European body of legislative texts

The definition of ATMPs is laid down in Reg 1394/2007 modifying Dir 2001/83

Four Different types of ATMPs:

- 1. Gene Therapy medicinal products (defined in Annex I part IV of Dir 2001/83 amended by Dir 2009/120)
- 2. Cell Therapy medicinal products (defined in Annex I part IV of Dir 2001/83 amended by Dir 2009/120)
- 3. Tissue engineered products
- 4. Combined ATMPs

Somatic Cell Therapy Medicinal Product

(defined in Annex I part IV of Dir 2001/83 amended by Dir 2009/120)

Somatic cell therapy medicinal product means a biological medicinal product which has the following characteristics:

- (a)contains or consists of cells or tissues that have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or of cells or tissues that are not intended to be used for the same essential function(s) in the recipient and the donor;
- (b) is presented as having properties for, or is used in or administered to human beings with a view to **treating**, **preventing or diagnosing a disease** through the pharmacological, immunological or metabolic action of its cells or tissues.




Replacement vs new function:






Replacement vs new function:





Replacement vs new function:





 cells or tissues that are not intended to be used for the same essential function(s) in the recipient and the donor


The CAT classification is based on two different criteria: location and function


Replacement on an original function may require the same anatomical or histological environment, especially for epithelial cells



Homologous vs/Non homologous use Reflection paper on classification of ATMPs EMA/CAT/600280/2010

Replacement: epithelium









Homologous vs/Non homologous use Reflection paper on classification of ATMPs EMA/CAT/600280/2010


 Cell dissociation means modification of histology and function except when reimplantation in the same epithelium







Islet preparation retains histological structure and function








 cells or tissues that are not intended to be used for the same essential function(s) in the recipient and the donor

The CAT classification is based on two different criteria: location and function

For **mesenchymal cells**, the function is not dependent on the histological location




different function






Hematopoietic stem cells for bone marrow transplantation not manipulated for homologous use





Stromal Vascular Fraction



- Autologous, non-manipulated lipoaspirate containing adipocytes and stromal vascular fraction
- ✓ intended to act as a natural autologous lipofiller.
- √ Was classified as Not ATMP in 2012

Could be considered now as somatic cell therapy if manufacturing process is considered a substantial manipulation



- New function
- The cells or tissues have a different function in donor and recipient
 - CD34+ cells in heart muscle
 - Bone marrow cells for bone of joint healing



THE MESENGENIC PROCESS Bone Marrow/Periosteum Mesenchymal Stem Cell (MSC) MSC Proliferation Proliferation Marrow Stroma Ligamentogenesis Tendogenesis/ Adipogenesis Osteogenesis Chondrogenesis Myogenesis Other "Commitment" Transitory Transitory Transitory preadipocyte Transitory Osteoblast Chondrocyte **Eibroblast** Myoblast Stromal Cell Lineage Progression Chondrocyte Osteoblast early adipocyte Mesenchymal Tissue Myoblast Fusion Differentiation Unique Micro-niche Maturation Hypertrophic Stromal T/L Myotube Osteocyte Dermal and Chondrocyte Cells **Fibroblast** Adipocyte Other Cells ADIPOSE CONNECTIVE TENDON/ BONE CARTILAGE MUSCLE MARROW TISSUE LIGAMENT TISSUE

Non homologous use

- ✓ Bone marrow-derived autologous CD34 cells
- ✓ Intended for improvement of heart function in patients with refractory angina and chronic myocardial ischemia
- √ Tissue-engineered product
- √ 22/03/2012

Non homologous use

- ✓ Autologous bone marrow cell aspirate in autologous plasma
- ✓ Intended for treatment of osteoarthrosis and osteochondral lesion
- ✓ Now considered as Tissue-engineered product
- √ 28/05/14

Formerly classified as non ATMP

CONCLUSION

- ✓ It is not always easy to define the « same essential function of a cell in a donor and a recipient »
- ✓ The CAT classification is based on existing scientific knowledge of cell biology. Classification may vary according to the evolution of science